专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06699870B2 Phthalazine compounds and therapeutic agents for erectile dysfunction 失效
标题翻译：酞嗪类化合物和勃起功能障碍治疗剂
公开(公告)号：US06699870B2
公开(公告)日：2004-03-02
申请号：US10281194
申请日：2002-10-28
申请人： Nobuhisa Watanabe , Norio Karibe , Kazuki Miyazaki , Fumihiro Ozaki , Atsushi Kamada , Shuhei Miyazawa , Yoshimitsu Naoe , Toshihiko Kaneko , Itaru Tsukada , Tadashi Nagakura , Hiroki Ishihara , Kohtarou Kodama , Hideyuki Adachi
发明人： Nobuhisa Watanabe , Norio Karibe , Kazuki Miyazaki , Fumihiro Ozaki , Atsushi Kamada , Shuhei Miyazawa , Yoshimitsu Naoe , Toshihiko Kaneko , Itaru Tsukada , Tadashi Nagakura , Hiroki Ishihara , Kohtarou Kodama , Hideyuki Adachi
IPC分类号： A61K31502
CPC分类号： C07D231/12 , C07D233/56 , C07D237/28 , C07D237/34 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D409/14 , C07D411/14 , C07D417/04 , C07D417/14 , C07D451/06 , C07D471/08 , C07D491/04 , C07D491/08 , C07D491/10
摘要： The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1 and R2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1 is a chlorine atom, R2 is a methoxy group and Y is a 5- or 6-memberred amine ring substituted with a hydroxyl group is excluded.
摘要翻译：本发明提供作为下式表示的勃起功能障碍治疗剂的酞嗪化合物，其药理学上可接受的盐或其水合物：其中R 1和R 2彼此相同或不同，可以被卤素原子取代的C1〜C4烷基，可被卤素原子或氰基取代的C1〜C4烷氧基; X表示氰基，硝基，卤素原子，可被取代的羟基亚氨基或可被取代的杂芳基; Y表示可以被取代的杂芳基，可以被取代的芳基，可以被取代的炔基，烯基，烷基，任选取代的饱和或不饱和的4-至8-元胺环，环胺化合物是单环化合物，双环化合物或螺环化合物; l为1〜3的整数，条件是其中l为1或2，X为氰基，硝基或氯原子，R 1为氯原子，R 2为甲氧基，Y为5-或6 被羟基取代的胺基环被排除。

2. 发明授权

US06498159B1 Phthalazine derivatives and remedies for erectile dysfunction 失效
标题翻译：酞嗪衍生物和勃起功能障碍的治疗方法
公开(公告)号：US06498159B1
公开(公告)日：2002-12-24
申请号：US09508197
申请日：2000-03-08
申请人： Nobuhisa Watanabe , Norio Karibe , Kazuki Miyazaki , Fumihiro Ozaki , Atsushi Kamada , Shuhei Miyazawa , Yoshimitsu Naoe , Toshihiko Kaneko , Itaru Tsukada , Tadashi Nagakura , Hiroki Ishihara , Kohtarou Kodama , Hideyuki Adachi
发明人： Nobuhisa Watanabe , Norio Karibe , Kazuki Miyazaki , Fumihiro Ozaki , Atsushi Kamada , Shuhei Miyazawa , Yoshimitsu Naoe , Toshihiko Kaneko , Itaru Tsukada , Tadashi Nagakura , Hiroki Ishihara , Kohtarou Kodama , Hideyuki Adachi
IPC分类号： A61K31502
CPC分类号： C07D231/12 , C07D233/56 , C07D237/28 , C07D237/34 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D409/14 , C07D411/14 , C07D417/04 , C07D417/14 , C07D451/06 , C07D471/08 , C07D491/04 , C07D491/08 , C07D491/10
摘要： The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1 and R2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1 is a chlorine atom, R2 is a methoxy group and Y is a 5- or 6-membered amine ring substituted with a hydroxyl group is excluded.
摘要翻译：本发明提供作为下述式表示的勃起功能障碍治疗剂的酞嗪化合物，其药理学上可接受的盐或其水合物：其中R1和R2彼此相同或不同，表示卤素原子，可以被卤素原子取代的C1〜C4烷基，可被卤素原子或氰基取代的C1〜C4烷氧基; X表示氰基，硝基，卤素原子，可被取代的羟基亚氨基或可被取代的杂芳基; Y表示可以被取代的杂芳基，可以被取代的芳基，可以被取代的炔基，烯基，烷基，任选取代的饱和或不饱和的4-至8-元胺环，环胺化合物是单环化合物，双环化合物或螺环化合物; l为1〜3的整数，条件是其中l为1或2的情况，X为氰基，硝基或氯原子，R 1为氯原子，R 2为甲氧基，Y为被5或6元环取代的5-或6-元胺环不包括羟基。

3. 发明授权

US5849741A Fused pyridazine compounds 失效
标题翻译：稠合哒嗪化合物
公开(公告)号：US5849741A
公开(公告)日：1998-12-15
申请号：US619621
申请日：1996-04-09
申请人： Nobuhisa Watanabe , Yasuhiro Kabasawa , Yasutaka Takase , Fumihiro Ozaki , Keiji Ishibashi , Kazuki Miyazaki , Masayuki Matsukura , Shigeru Souda , Kazutoshi Miyake , Hiroki Ishihara , Kohtaro Kodama , Hideyuki Adachi
发明人： Nobuhisa Watanabe , Yasuhiro Kabasawa , Yasutaka Takase , Fumihiro Ozaki , Keiji Ishibashi , Kazuki Miyazaki , Masayuki Matsukura , Shigeru Souda , Kazutoshi Miyake , Hiroki Ishihara , Kohtaro Kodama , Hideyuki Adachi
IPC分类号： C07D237/34 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04 , C07D521/00 , A01K31/50 , C07D237/30
CPC分类号： C07D231/12 , C07D233/56 , C07D237/34 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04
摘要： A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE"). The compounds are useful as preventive and therapeutic agents for diseases for which a cGMP-PDE inhibiting action is efficacious, for example, ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute cardiac failure, pulmonary hypertension, arteriosclerosis and bronchial asthma. ##STR1##
摘要翻译： PCT No.PCT / JP95 / 01575 Sec。 371日期：1996年4月9日 102（e）日期1996年4月9日PCT提交1995年8月8日PCT公布。出版物WO96 / 05176 日期：1996年2月22日由下述通式（I）表示的稠合哒嗪化合物或其对环状GMP磷酸二酯酶具有抑制活性的药理学上可接受的盐（以下称为“cGMP-PDE”）。所述化合物可用作对于cGMP-PDE抑制作用有效的疾病的预防和治疗剂，例如心绞痛，心肌梗塞，慢性和急性心力衰竭，肺动脉高压，动脉硬化和支气管哮喘等缺血性心脏病。（一）

4. 发明授权

US06218392B1 Fused pyridazine compounds 失效
标题翻译：稠合哒嗪化合物
公开(公告)号：US06218392B1
公开(公告)日：2001-04-17
申请号：US09161946
申请日：1998-09-29
申请人： Nobuhisa Watanabe , Yasuhiro Kabasawa , Yasutaka Takase , Fumihiro Ozaki , Keiji Ishibashi , Kazuki Miyazaki , Masayuki Matsukura , Shigeru Souda , Kazutoshi Miyake , Hiroki Ishihara , Kohtaro Kodama , Hideyuki Adachi
发明人： Nobuhisa Watanabe , Yasuhiro Kabasawa , Yasutaka Takase , Fumihiro Ozaki , Keiji Ishibashi , Kazuki Miyazaki , Masayuki Matsukura , Shigeru Souda , Kazutoshi Miyake , Hiroki Ishihara , Kohtaro Kodama , Hideyuki Adachi
IPC分类号： A61K31502
CPC分类号： C07D231/12 , C07D233/56 , C07D237/34 , C07D249/08 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04
摘要： A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as “cGMP-PDE”). The compounds are useful as preventive and therapeutic agents for diseases for which a cGMP-PDE inhibiting action is efficacious, for example, ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute cardiac failure, pulmonary hypertension, arteriosclerosis and bronchial asthma.
摘要翻译：由下述通式（I）表示的稠合哒嗪化合物或其对环状GMP磷酸二酯酶具有抑制活性的药理学上可接受的盐（以下称为“cGMP-PDE”），可用作预防和治疗剂 cGMP-PDE抑制作用有效的疾病，例如心绞痛，心肌梗死，慢性和急性心力衰竭，肺动脉高压，动脉硬化和支气管哮喘等缺血性心脏病。

5. 发明授权

US06784192B2 Piperidine compound and pharmaceutical composition thereof 失效
标题翻译：新型哌啶化合物及其药物组合物。
公开(公告)号：US06784192B2
公开(公告)日：2004-08-31
申请号：US10181560
申请日：2002-07-19
申请人： Fumihiro Ozaki , Toshihiko Kaneko , Mutsuko Tabata , Yoshinori Takahashi , Kazuki Miyazaki , Junichi Kamata , Ichiro Yoshida , Masayuki Matsukura , Hiroyuki Suzuki , Takashi Yoshinaga , Hiroki Ishihara , Hiroshi Katoh , Kohei Sawada , Tatsuhiro Onogi , Kiyoaki Kobayashi , Miyuki Ohkubo
发明人： Fumihiro Ozaki , Toshihiko Kaneko , Mutsuko Tabata , Yoshinori Takahashi , Kazuki Miyazaki , Junichi Kamata , Ichiro Yoshida , Masayuki Matsukura , Hiroyuki Suzuki , Takashi Yoshinaga , Hiroki Ishihara , Hiroshi Katoh , Kohei Sawada , Tatsuhiro Onogi , Kiyoaki Kobayashi , Miyuki Ohkubo
IPC分类号： A61K31445
CPC分类号： C07D401/14 , C07D401/06 , C07D405/14 , C07D409/14 , C07D417/14
摘要： The present invention provides a novel compound having a superior Na+ channel inhibitory activity. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, the ring A represents a ring represented by the formula: (wherein R1 represents a hydrogen atom etc.; and R2 represents indicates a hydrogen atom and the like) etc.; W represents an optionally substituted C1-6 alkylene group etc.; Z represents an optionally substituted C6-14 aromatic hydrocarbon cyclic group etc.; and l represents an integer from 0 to 6.
摘要翻译：本发明提供具有优异的Na +通道抑制活性的新型化合物。即，它提供由下式（I）表示的化合物，其盐或它们的水合物。在该式中，环A表示由下式表示的环：其中R 1表示氢原子等 R 2表示氢原子等）等; W表示任选取代的C 1-6亚烷基等; Z表示任选取代的C 6-14芳烃环基等。 l表示0〜6的整数。

6. 发明申请

US20060247259A1 Nitrogen-containing aromatic derivatives 有权
公开(公告)号：US20060247259A1
公开(公告)日：2006-11-02
申请号：US11293785
申请日：2005-12-02
申请人： Yasuhiro Funahashi , Akihiko Tsuruoka , Masayuki Matsukura , Toru Haneda , Yoshio Fukuda , Junichi Kamata , Keiko Takahashi , Tomohiro Matsushima , Kazuki Miyazaki , Ken-ichi Nomoto , Tatsuo Watanabe , Hiroshi Obaishi , Atsumi Yamaguchi , Sachi Suzuki , Katsuji Nakamura , Fusayo Mimura , Yuji Yamamoto , Junji Matsui , Kenji Matsui , Takako Yoshiba , Yasuyuki Suzuki , Itaru Arimoto
发明人： Yasuhiro Funahashi , Akihiko Tsuruoka , Masayuki Matsukura , Toru Haneda , Yoshio Fukuda , Junichi Kamata , Keiko Takahashi , Tomohiro Matsushima , Kazuki Miyazaki , Ken-ichi Nomoto , Tatsuo Watanabe , Hiroshi Obaishi , Atsumi Yamaguchi , Sachi Suzuki , Katsuji Nakamura , Fusayo Mimura , Yuji Yamamoto , Junji Matsui , Kenji Matsui , Takako Yoshiba , Yasuyuki Suzuki , Itaru Arimoto
IPC分类号： A61K31/519 , A61K31/517 , A61K31/4745 , A61K31/4706 , C07D487/02 , C07D471/02
CPC分类号： C07D213/73 , A61K31/4706 , A61K31/4745 , A61K31/517 , A61K31/519 , C07D207/34 , C07D213/26 , C07D213/68 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D215/18 , C07D215/233 , C07D215/36 , C07D215/38 , C07D215/48 , C07D239/34 , C07D239/42 , C07D239/47 , C07D239/88 , C07D249/04 , C07D261/14 , C07D277/48 , C07D307/68 , C07D319/06 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/04 , C07D495/04
摘要： Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.

7. 发明授权

US06352989B1 Nitrogenous heterocyclic derivatives and medicine thereof 有权
标题翻译：氮杂环衍生物及其药物
公开(公告)号：US06352989B1
公开(公告)日：2002-03-05
申请号：US09600995
申请日：2000-07-26
申请人： Kazuki Miyazaki , Yasutaka Takase , Takao Saeki
发明人： Kazuki Miyazaki , Yasutaka Takase , Takao Saeki
IPC分类号： A61K31505
CPC分类号： C07D215/38 , C07D239/84 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/04 , C07D471/04
摘要： The present invention provides a novel nitrogen-containing heterocyclic compound useful as a phosphodiesterase-4 inhibitor, and a medicament comprising the same. Further, the present invention provides a nitrogen-containing heterocyclic compound represented by the following formula, its salt or hydrates thereof, and a medicament comprising the same. wherein the ring A is an aromatic hydrocarbon ring which may have a heteroatom, the ring B represents (a) a saturated hydrocarbon ring, (b) an unsaturated hydrocarbon ring, (c) a saturated heterocyclic ring or (d) an unsaturated heterocyclic ring, all of which may have a substituent group.
摘要翻译：本发明提供了可用作磷酸二酯酶-4抑制剂的新型含氮杂环化合物和包含其的药物。此外，本发明提供下式表示的含氮杂环化合物，其盐或水合物，以及含有该杂环化合物的药物，其中环A为可具有杂原子的芳香烃环，环B为（a）饱和烃环，（b）不饱和烃环，（c）饱和杂环或（d）不饱和杂环，它们都可以具有取代基。

8. 发明申请

US20100256191A1 AMPA RECEPTOR ANTAGONISTS AND ZONISAMIDE FOR EPILEPSY 审中-公开
标题翻译： AMPA受体拮抗剂和紫杉烷
公开(公告)号：US20100256191A1
公开(公告)日：2010-10-07
申请号：US12744444
申请日：2008-12-26
申请人： Takahisa Hanada , Shigeki Hibi , Kazuki Miyazaki
发明人： Takahisa Hanada , Shigeki Hibi , Kazuki Miyazaki
IPC分类号： A61K31/444 , A61K31/423 , A61P25/08
CPC分类号： A61K45/06 , A61K31/423 , A61K31/444 , A61K2300/00
摘要： The invention provides methods for treating epilepsy by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with zonisamide useful for treating epilepsy. The invention also provides pharmaceutical combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists, and optionally, zonisamide that are useful for treating epilepsy.
摘要翻译：本发明提供了通过向患者施用治疗有效量的AMPA受体拮抗剂与用于治疗癫痫的唑尼沙胺组合来治疗癫痫的方法。本发明还提供药物组合，试剂盒和药物组合物，其包含治疗有效量的AMPA受体拮抗剂和任选的可用于治疗癫痫的唑尼沙胺。

9. 发明授权

US06593233B1 Semiconductor device and method for manufacturing the same 失效
标题翻译：半导体装置及其制造方法
公开(公告)号：US06593233B1
公开(公告)日：2003-07-15
申请号：US09093819
申请日：1998-06-09
申请人： Kazuki Miyazaki , Kazunobu Shigehara , Masanobu Zenke
发明人： Kazuki Miyazaki , Kazunobu Shigehara , Masanobu Zenke
IPC分类号： H01L2144
CPC分类号： H01L21/76877 , H01L21/76838 , H01L23/5226 , H01L23/53257 , H01L2924/0002 , H01L2924/00
摘要： In a semiconductor device having a metal wiring conductor connected to a contact hole formed through an interlayer insulator layer formed on a lower level circuit, a lower level tungsten film is deposited under a condition giving an excellent step coverage so as to fill the contact hole, and an upper level tungsten film is further deposited under a condition of forming a film having a stress smaller than that of the lower level tungsten film. The metal wiring conductor is formed of a double layer which is composed of the lower level tungsten film and the upper level tungsten film, and therefore, has a reduced stress in the whole of the film. Thus, there is obtained the tungsten film wiring conductor which fills the inside of the contact hole with no void and therefore has a high reliability, and which has a low film stress. In addition, the number of steps in the manufacturing process can be reduced.
摘要翻译：在具有连接到通过形成在下层电路上的层间绝缘体层形成的接触孔的金属布线导体的半导体器件中，在提供优良阶梯覆盖的条件下沉积下层钨膜以便填充接触孔，并且在形成具有比下层钨膜的应力小的膜的膜的条件下进一步沉积上层钨膜。金属布线导体由下层钨膜和上层钨膜构成的双层形成，因此整个膜的应力减小。因此，获得了没有空隙填充接触孔内部的钨膜布线导体，因此具有高的可靠性，并且膜应力低。此外，可以减少制造过程中的步骤数。

10. 发明申请

US20100297181A1 AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ 审中-公开
标题翻译： AMPA受体拮抗剂用于癫痫，精神障碍或感觉器官缺陷
公开(公告)号：US20100297181A1
公开(公告)日：2010-11-25
申请号：US12744454
申请日：2008-12-26
申请人： Takahisa Hanada , Shigeki Hibi , Kazuki Miyazaki
发明人： Takahisa Hanada , Shigeki Hibi , Kazuki Miyazaki
IPC分类号： A61K31/444 , A61K31/496 , A61K39/08 , A61K31/55 , A61K31/5513 , A61K31/4985 , A61K31/675 , A61K31/53 , A61K31/542 , A61K31/57 , C07D213/22 , A61P25/08 , A61P25/22 , A61P25/18 , A61P27/16 , A61P27/06 , A61P25/24 , A61P9/10
CPC分类号： A61K45/06 , A61K31/4412 , A61K2300/00
摘要： The invention provides methods for treating epilepsy, mental disorders and/or deficits in sensory organ by administering to patients therapeutically effective amounts of AMPA receptor antagonists in combination with one or more other active ingredients useful for treating epilepsy, mental disorders and/or deficits in sensory organ. The invention also provides pharmaceutical combinations, kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists, and optionally, one or more other active ingredients that are useful for treating epilepsy, mental disorders and/or deficits in sensory organ.
摘要翻译：本发明提供了通过向患者施用治疗有效量的AMPA受体拮抗剂与用于治疗癫痫的一种或多种其它活性成分，精神障碍和/或感觉缺陷来治疗癫痫症，精神障碍和/或感觉器官缺陷的方法器官。本发明还提供药物组合，试剂盒和药物组合物，其包含治疗有效量的AMPA受体拮抗剂和任选的一种或多种可用于治疗感觉器官的癫痫，精神障碍和/或缺陷的其它活性成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式